



Diarmuid O'Brien  
Chief Executive, Cambridge Enterprise

Andrew Williamson,  
Managing Partner, Cambridge Innovation Capital



18<sup>th</sup> October 2022

Cambridge Enterprise

Responsible for supporting the translation of University of Cambridge research to create globally leading economic and social impact.





## Portfolio Company Characteristics

- **Technology** – protected, differentiated and scalable
- **Team** – energetic, willing to learn and balanced (technical and commercial)
- **Market** – understanding of fit and engagement with customers
- **Revenue & Capital** – realistic understanding of opportunity and capital requirement
- **Vision**
- **Advisors** – market connections

# Cambridge Innovation Capital

Venture capital firm,  
founded to invest in  
deeptech and life  
science companies  
connected to  
Cambridge, UK



## Portfolio Company Characteristics

- **Technology** – IP protected and enabling disruption
- **Team** – Core leadership team with track record of scaling deeptech/biotech innovation
- **Market** – Go-To-Market plan, past POC and beginning to scale
- **Revenue** –scalable revenue model with proof of traction
- **Capital** - needs of £10-100m prior to raising growth capital

# Gyroscope Therapeutics

- A clinical-stage gene therapy company focused on treating diseases of the eye
- Cambridge Enterprise invested in the seed round
- CIC invested in Series B and Series C round in 2021
- Acquired by Novartis for up to \$1.5bn in Dec. 2021

Thank you

